Table 4 Summary of trials exploring regiments treated for adult LCH patients
Year | Author | patient number | Fisrt line regimen | Overall response rate | PFS or reactivation | 3–4 grade hematological toxicity |
|---|---|---|---|---|---|---|
1999 | Alan Saven | 13 | Cladribine | 75% | N/A | Neutropenia 7/13 (53.8%) |
2012 | Maria A. Cantu | 19 | Vinblastine+ prednisone | 16% | N/A | 75% |
22 | 2-CdA | 41% | N/A | 37% | ||
24 | ARA-C | 79% | N/A | 20% | ||
2013 | Z. ADAM | 7 | Cladribine | 86% | N/A | Neutropenia 6/7 (86%) |
2015 | Enrico Derenzini | 11 | MACOP-B | 100% | Overall 64% | Neutropenia 4/11 (36.4%) |
2016 | Duan MH | 31 | CEVP | 68.8% | Reactivation rate 73.3% | Neutropenia 35.6% Thrombocytopenia 8.9% |
14 | VP | 70% | Reactivation rate 71% | Neutropenia 48.4% Thrombocytopenia 12.9% |